Skip to content

EBIT at other companies

Immunome logo
ImmunomeIMNM
-$59.33M-32.9%
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
-$19.21M+35.1%
Abbott logo
AbbottABT
Guardant Health logo
Guardant HealthGH
Natera, Inc. logo
Natera, Inc.NTRA
Tempus AI, Inc. logo
Tempus AI, Inc.TEM

Other financials

Income statement

See full
Revenue$40.8M+28.1%
Operating income-$135.8M+11.6%
Net income-$93.2M+12.3%
EPS (diluted)-$2.29+26.1%

Balance sheet

See full
Cash & equivalents$76.3M-44.4%
Total debt$51.0M-20.7%
Total equity$2.5B+3.6%
Total assets$2.8B-1.5%

Cash flow

See full
Operating cash flow-$87.0M+8.4%
CapEx$503.0K+711%
Free cash flow-$87.5M+8.0%

Valuation

See full
Market cap$2.62B+145%
Enterprise value$2.6B+164%
P/S16.8×+8.6×

Profitability

See full
Operating margin-348.7%-153pp
Net margin-253.2%-115pp
FCF margin-187.2%-60.4pp

Returns & leverage

See full
Return on equity-16.1%
Debt / equity0.0×
Current ratio11.7×+2.0×

Where this comes from

Calculated from GRAIL, Inc.’s reported figures.

Plus components not separately reported this period.

The official record: GRAIL, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about GRAIL, Inc.'s ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is GRAIL, Inc.'s EBIT?
GRAIL, Inc. (GRAL) reported EBIT of -$135.77M in Q1 2026.
How has GRAIL, Inc.'s EBIT changed year-over-year?
GRAIL, Inc.'s EBIT increased by 11.6% year-over-year, from -$153.61M to -$135.77M.
What is the long-term trend for GRAIL, Inc.'s EBIT?
Over 3 years (2022 to 2025), GRAIL, Inc.'s EBIT has grown at a -53.1% compound annual growth rate (CAGR), from -$5.44B to -$562.16M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.